top of page
Hide and Seek

11/27/2022

Tenacia Biotechnology (Shanghai) Co., Ltd. is an emerging biotech headquartered in China, dedicated to the development of new drugs for central nervous system diseases.

Tenacia recently introduced exclusive development and commercialization rights for certain formulations of the new drug Ganaxolone in China, Hong Kong, Macau and Taiwan from US-listed Marinus Pharmaceuticals Inc. Under the collaboration agreement, Marinus will receive an initial payment of $10 million and milestone payments of up to $256 million based on specific regulatory registration, clinical progress and commercialization milestones, as well as tiered low double-digit royalties based on net sales.

bottom of page